enGene

CG Oncology

This biopharmaceutical company develops oncolytic immunotherapies for patients with non-muscle invasive bladder cancer.

ArTara Therapeutics

This clinical-stage biopharmaceutical company develops cell therapies and replacement treatments for patients with non-muscle invasive bladder cancer and rare metabolic diseases.

Engage Bio

This biotechnology company develops non-viral genetic medicines and mRNA immunotherapies for pharmaceutical partners to treat cancer and gene replacement disorders.

Ensoma

This company develops in vivo genomic medicines and vector delivery platforms to engineer blood and immune cells for patients with genetic diseases and cancer.

Aura Biosciences

This biotechnology company develops virus-like drug conjugates to treat patients with solid tumours, specifically targeting ocular and bladder cancers.

UroGen Pharma

This company develops and commercialises hydrogel-based medicines for patients with urological and specialty cancers, including treatments for low-grade upper tract urothelial carcinoma and bladder cancer.

Anjarium BioSciences

This company develops non-viral gene therapies and synthetic DNA vectors for patients with genetic diseases and life sciences researchers.

Sonothera Therapeutics

This company develops a non-viral gene therapy platform using ultrasound and microbubbles to deliver genetic medicines for patients with serious diseases.